Literature DB >> 34113039

Questions swirl around failures of disease-modifying Huntington's drugs.

Cormac Sheridan1.   

Abstract

Entities:  

Year:  2021        PMID： 34113039     DOI： 10.1038/s41587-021-00955-y

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Canadian healthcare capacity gaps for disease-modifying treatment in Huntington's disease: a survey of current practice and modelling of future needs.

Authors:  Angèle Bénard; Sylvain Chouinard; Blair R Leavitt; Nathalie Budd; Jennifer W Wu; Kerrie Schoffer
Journal:  BMJ Open       Date:  2022-06-01       Impact factor: 3.006

2.  Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease.

Authors:  Jun Wan Shin; Aram Shin; Seri S Park; Jong-Min Lee
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-04       Impact factor: 6.698

3.  PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington's disease.

Authors:  Jun Wan Shin; Eun Pyo Hong; Seri S Park; Doo Eun Choi; Sophia Zeng; Richard Z Chen; Jong-Min Lee
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-14       Impact factor: 5.849

Review 4.  Domestication of newly evolved hexaploid wheat-A journey of wild grass to cultivated wheat.

Authors:  Sasha Gohar; Muhammad Sajjad; Sana Zulfiqar; Jiajun Liu; Jiajie Wu; Mehboob-Ur- Rahman
Journal:  Front Genet       Date:  2022-10-03       Impact factor: 4.772
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.